Clinical Trial Detail

NCT ID NCT02936323
Title PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Recruitment Recruiting
Gender both
Phase
Variant Requirements yes
Sponsors
Indications

adrenal medulla cancer

large cell neuroendocrine carcinoma

neuroendocrine tumor

paraganglioma

thyroid medullary carcinoma

lung small cell carcinoma

Merkel cell carcinoma

Therapies

PEN-221

Age Groups: adult senior

Additional content available in CKB BOOST